NCT05335031Completed
A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)
Ozanimod (Zeposia®) In Patients With RRMS: A 3-Year, Multicenter, Prospective, Non-Interventional Study to Document Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany (OZEAN)
Source: ClinicalTrials.gov · Last updated 8 Sept 2025
Brief summary (registry, in English)
The purpose of this study is to collect real-world data and to gain insights about long-term usage of ozanimod (Zeposia ®), its effect on well-defined outcome parameters comprising participant-relevant outcomes, as well as quality of life, effectiveness, and incidence of adverse events.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 450 (actual)
- First submitted
- 12 Apr 2022
- Start date
- 3 Mar 2021
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Multiple sclerosis
- NCT number
- NCT05335031
What you commit to
- Study type: Observational
- Participants enrolled: 450
- From 3 Mar 2021 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Hypersensitivity to the active substance(s) or to any of the excipients of ozanimod as specified in the prescribing information must not be enrolled
Other
- Special warnings, precautions and contraindications specified in the current version of the Summary of Product Characteristics (SmPC)
- Participation in any other clinical studies
- Other protocol-defined inclusion/exclusion criteria apply
Who the study is looking for
- Confirmed diagnosis of relapsing-remitting multiple sclerosis (RRMS)
- The decision upon treatment with ozanimod must have been made before enrollment and independently of this non-interventional observational study
- All data on ozanimod treatment are collected prospectively. The retrospective documentation of ozanimod therapy and enrollment of participants that are already on ozanimod therapy is not allowed
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitätsklinikum Dresden, MS Ambulanz Coordinator of this site? Confirm its status | Dresden | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.